INmune Bio (NASDAQ:INMB) Announces Earnings Results

INmune Bio (NASDAQ:INMB) released its quarterly earnings data on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.16, Zacks reports.

Here are the key takeaways from INmune Bio’s conference call:

• Positive Sentiment: INmune Bio expects to submit Ebstrocel’s U.K. marketing authorization application by the end of Q3 or early Q4 2026, followed by EMA and U.S. submissions in early 2027. MHRA alignment across clinical, non-clinical, and CMC requirements, plus approval of the pediatric investigation plan, reduces regulatory uncertainty.
• Positive Sentiment: Ebstrocel manufacturing and supply-chain readiness advanced, including commercial-ready cord-tissue processing, transfer of MSC isolation to the intended commercial facility, and expanded access to umbilical cord tissue through Anthony Nolan. Management believes this supports scalable supply for potential U.K., European, and U.S. commercialization.
• Positive Sentiment: XPro received FDA Fast Track designation for early Alzheimer’s disease, while the MINDFuL Phase II study showed statistically significant improvement in white-matter myelin MRI biomarkers. Management is advancing a registrational strategy and evaluating partnerships, although Alzheimer’s remains the clinical priority.
• Neutral Sentiment: The company reported $18.4 million in cash at June 30 and received a subsequent $4.2 million Australian R&D rebate, with funding expected to last into Q2 2027. Management estimates a forward burn rate of roughly $1 million to $1.5 million per month and expects to raise capital selectively, but future financing could still create dilution.
• Positive Sentiment: If approved, management estimates a U.K. opportunity of roughly 800 RDEB patients and anticipates pricing of approximately £400,000–£500,000 per child annually, subject to reimbursement negotiations. The company also highlighted a potential U.S. rare pediatric disease priority review voucher, which it estimates could be worth $100 million to $200 million, though neither approval nor monetization is assured.

INmune Bio Price Performance

INmune Bio stock traded up $0.17 during trading hours on Friday, hitting $2.08. The company had a trading volume of 952,600 shares, compared to its average volume of 509,155. The firm has a market cap of $55.42 million, a PE ratio of -3.11 and a beta of 0.97. INmune Bio has a one year low of $1.09 and a one year high of $2.61. The firm has a 50-day moving average of $1.63 and a 200 day moving average of $1.48.

Institutional Investors Weigh In On INmune Bio

A number of institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new position in shares of INmune Bio in the fourth quarter valued at approximately $32,000. XTX Topco Ltd lifted its holdings in INmune Bio by 41.3% during the 4th quarter. XTX Topco Ltd now owns 68,865 shares of the company’s stock worth $107,000 after purchasing an additional 20,121 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in INmune Bio during the 4th quarter worth approximately $26,000. Jain Global LLC acquired a new stake in INmune Bio during the 4th quarter worth approximately $66,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in INmune Bio by 20.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock valued at $78,000 after purchasing an additional 8,427 shares during the period. Institutional investors own 12.72% of the company’s stock.

Analyst Ratings Changes

INMB has been the topic of a number of research analyst reports. Weiss Ratings cut INmune Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. Wall Street Zen raised shares of INmune Bio from a “sell” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.